Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diet

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    992 result(s) found for: Diet. Displaying page 11 of 50.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    EudraCT Number: 2017-002407-10 Sponsor Protocol Number: 17/0238 Start Date*: 2018-03-23
    Sponsor Name:University College London
    Full Title: A double-blinded, randomised, placebo-controlled trial of liraglutide 3.0 mg in patients with poor weight-loss and a suboptimal glucagon-like peptide-1 response following bariatric surgery.
    Medical condition: Obesity.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10068900 Bariatric surgery LLT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-003175-34 Sponsor Protocol Number: DAPARHT Start Date*: 2022-02-09
    Sponsor Name:Oslo University Hospital
    Full Title: DAPARHT: DAPAgliflozin for Renal protection in Heart Transplant recipients
    Medical condition: heart transplant recipients in follow-up
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005058-27 Sponsor Protocol Number: 165-306 Start Date*: Information not available in EudraCT
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase 3 Multi-Center Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase in Adolescent Subjects (Ages 12-17) with Phenylketonuria Featuring an Open-Label Randomized...
    Medical condition: Phenylketonuria (PKU)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10034873 Phenylketonuria (PKU) LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004626-28 Sponsor Protocol Number: SymSF2 Start Date*: 2019-07-18
    Sponsor Name:SymbioPharm GmbH
    Full Title: Randomized, double-blind, placebo-controlled, multi-centre trial to evaluate the efficacy, safety and tolerability of oral treatment with living bacteria of E. coli DSM 17252 (Symbioflor®2) in pati...
    Medical condition: Diarrhoea-predominant irritable bowel syndrome with recurrent abdominal pain according to Rome IV criteria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004935-22 Sponsor Protocol Number: TA-8995-303 Start Date*: 2020-10-01
    Sponsor Name:NewAmsterdam Pharma BV
    Full Title: A Placebo-Controlled, Double-Blind, Randomized Phase 2 Study to Evaluate the Effect of Obicetrapib in Combination with Ezetimibe in Participants with Mild Dyslipidemia
    Medical condition: mild dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10020049 High cholesterol LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003036-20 Sponsor Protocol Number: 1-2016 Start Date*: 2017-10-02
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: A randomized trial of multifactorial primary prevention in high risk subjects candidate to a lung cancer early detection CT program
    Medical condition: health subjects (multifactorial primary prevention)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10036654 Prevention LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002191-41 Sponsor Protocol Number: AIDIT Start Date*: Information not available in EudraCT
    Sponsor Name:Uppsala University
    Full Title: Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
    Medical condition: Type 1 diabetes
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-002940-86 Sponsor Protocol Number: SELLIFA-02 Start Date*: 2007-08-24
    Sponsor Name:Cliniques Universitaires Saint-Luc – Université catholique de Louvain
    Full Title: Sepsis, Endothelial function, and Lipids in critically ill patients with Liver Failure (SELLIFA). Nutritional sub-study : Randomized controlled trial comparing the tolerance on lipid metabolism and...
    Medical condition: Liver failure, Liver cirrhosis, critical illness, total nutritional support
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009211 Cirrhosis liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003760-38 Sponsor Protocol Number: E7001-H001 Start Date*: 2005-10-14
    Sponsor Name:Sten Madsbad
    Full Title: Effect of three doses of nasal glp-1 versus placebo on postprandial hyperglycaemia in type 2 diabetes.
    Medical condition: postprandial hyperglycaemia in type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    10045242
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000301-45 Sponsor Protocol Number: BAY94-8862/14563 Start Date*: 2011-05-11
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-blind, multi-center study to assess safety and tolerability of different oral doses of BAY 94-8862 in subjects with stable chronic heart failure with left ventricular systolic...
    Medical condition: Stable chronic heart failure subjects with left ventricular systolic dysfunction and mild (Part A) or moderate (Part B) chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DE (Completed) DK (Completed) BE (Completed) AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-004336-16 Sponsor Protocol Number: CC-93538-EE-001 Start Date*: 2021-09-29
    Sponsor Name:Celgene International II Sàrl
    Full Title: A Phase 3, Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subject...
    Medical condition: EOSINOPHILIC ESOPHAGITIS
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10064220 Eosinophilic esophagitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) PT (Completed) BE (Completed) PL (Completed) IT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2004-000540-24 Sponsor Protocol Number: CLAF237A2310 Start Date*: 2004-12-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, double-blind, randomized, active controlled study to compare the effect of long term treatment with LAF237 50 mg bid to gliclazide up to 320 mg daily in drug naïve patients with type...
    Medical condition: Type II Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) IE (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002241-30 Sponsor Protocol Number: CEC-3/CEL Start Date*: 2018-01-30
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: A phase IIa, double-blind, randomised, placebo-controlled, dose-finding study on the efficacy and tolerability of a 6-week treatment with ZED1227 capsules vs. placebo in subjects with well-controll...
    Medical condition: Treatment of celiac disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10007864 Celiac disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) FI (Completed) DE (Completed) AT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002778-30 Sponsor Protocol Number: CLAF237A2357 Start Date*: 2005-10-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of 12 Week Treatment with Vildagliptin (LAF237) 50 mg QD in Subjects with Impaire...
    Medical condition: Type II Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FI (Completed) SE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-003332-23 Sponsor Protocol Number: B1261007 Start Date*: 2013-03-21
    Sponsor Name:Pfizer Inc., 235 42nd Street, New York, NY 10017, USA
    Full Title: A phase 2, randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate the efficacy and safety of once-daily administration of a chemokine CCR2/5 receptor antagonis...
    Medical condition: Diabetic nephropathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) ES (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2022-002470-86 Sponsor Protocol Number: 20190218 Start Date*: 2023-05-08
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without...
    Medical condition: Overweight and Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001711-30 Sponsor Protocol Number: RIMON_R_00961 Start Date*: 2006-10-11
    Sponsor Name:sanofi aventis Groupe
    Full Title: A Pan-European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with impaired fast...
    Medical condition: abdominally obese patients with impaired fasting blood glucose with or without other comorbidities
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) BE (Completed) PT (Prematurely Ended) CZ (Completed) SI (Completed) FR (Completed) NL (Prematurely Ended) NO (Completed) FI (Prematurely Ended) SE (Prematurely Ended) DK (Prematurely Ended) LT (Prematurely Ended) HU (Completed) SK (Completed) GR (Completed) AT (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-015918-22 Sponsor Protocol Number: CRAD001A2429 Start Date*: 2010-05-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A 24 months, multi-center, open-label, randomized, controlled trial to investigate efficacy, safety and evolution of cardiovascular parameters in de novo renal transplant recipients after early cal...
    Medical condition: renal transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Completed) AT (Completed) BE (Completed) GR (Completed) LV (Completed) EE (Completed) LT (Prematurely Ended) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000265-12 Sponsor Protocol Number: E2007-G000-332 Start Date*: 2011-08-31
    Sponsor Name:Eisai Limited
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel-group Study with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generali...
    Medical condition: Primary Generalized Tonic-Clonic Seizures
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10018101 Generalised tonic-clonic seizures HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) LV (Completed) GR (Completed) AT (Completed) CZ (Completed) NL (Completed) PL (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000951-42 Sponsor Protocol Number: 1517-CL-0610 Start Date*: 2013-12-04
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
    Medical condition: Anemia in Chronic Kidney Disease patients not on Dialysis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002272 Anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) NL (Completed) CZ (Completed) SK (Completed) SI (Completed) PT (Completed) AT (Completed) IE (Completed) DK (Completed) FI (Completed) LV (Completed) SE (Completed) FR (Completed) HR (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 27 22:23:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA